|
Getting your Trinity Audio player ready...
|
IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company focused on Alzheimer’s disease, artificial intelligence, and drug discovery, is drawing renewed investor attention after Ascendiant Capital reiterated its BUY rating and increased its 12-month price target to $5.50, citing multiple potential catalysts expected throughout 2026.
Investor interest has already begun to build. On June 9, 2026, shares of IGC Pharma reached an intraday high of $0.30 before closing at $0.285, with volume reaching 1,308,653 shares, well above typical trading activity. Read entire report.
According to Ascendiant, the company is approaching two significant milestones expected during the second half of 2026: completion of enrollment and advancement of the Phase 2 CALMA clinical trial evaluating IGC-AD1, and the anticipated rollout of the company’s proprietary AI platform beta program.
Alongside IGC Pharma, Inc. (NYSE: IGC) watch CCH Holdings Ltd (NASDAQ: CCHH), Galaxy Payroll Group (NASDAQ: GLXG), Arcadia Biosciences (NASDAQ: RKDA) and Hitek Global Inc (NASDAQ: HKIT) all trading actively today.
The firm’s report highlights that IGC recently surpassed 80% patient enrollment in its Phase 2 CALMA study evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia. The company expects to complete enrollment and advance the trial during mid-to-late 2026.
Ascendiant also pointed to previously reported interim clinical data that demonstrated a clinically and statistically significant reduction in agitation compared with placebo among Alzheimer’s patients, supporting continued development of the program.
IGC Pharma currently maintains a pipeline of five therapeutic candidates targeting Alzheimer’s disease, including lead asset IGC-AD1 and TGR-63. Beyond addressing agitation symptoms, preclinical research has shown IGC-AD1 may help suppress two of the disease’s primary biological hallmarks amyloid plaques and tau tangles while earlier studies suggested potential benefits in reducing agitation, anxiety, and depression.
The opportunity remains substantial. Alzheimer’s disease affects millions of individuals globally and remains one of the largest unmet needs in healthcare, with limited treatment options currently available to slow progression or address the disease’s underlying causes.
Ascendiant believes continued clinical progress, additional trial data, and advancement of the company’s AI-powered healthcare initiatives could serve as meaningful catalysts moving forward. While acknowledging the risks associated with clinical-stage biotechnology companies, the firm noted that the potential market opportunity for successful Alzheimer’s therapeutics could reach into the billions of dollars.
With major clinical milestones approaching, increasing institutional coverage, expanding intellectual property protection, and a growing focus on AI-driven biotechnology, investors continue monitoring IGC Pharma as it advances its Alzheimer’s treatment pipeline and precision medicine strategy. Read entire report.